Behandling med duodenal-jejunal bypass-sleeve ved svær overvægt

Ulrich Rohde; Silas Gylvin; Peter Vilmann; Steffen Ulrik Friis; Ebbe Langholz; Tina Vilsbøll; Filip Krag Knop

Behandling med duodenal-jejunal bypass-sleeve ved svær overvægt

Translated title of the contribution: Duodenal-jejunal bypass sleeve - a potential alternative to bariatric surgery?

Ulrich Rohde, Silas Gylvin, Peter Vilmann, Steffen Ulrik Friis, Ebbe Langholz, Tina Vilsbøll, Filip Krag Knop

Abstract

Overweight and obesity are risk factors for several co-morbidities reducing life expectancy. Conservative treatment of obesity is generally ineffective in the long-term. Bariatric surgery has proven effective, but is associated with potential complications. Duodenal-jejunal bypass sleeve is a novel minimal invasive and fully reversible endoscopic treatment modality approved for treatment of obesity with or without concomitant type 2 diabetes. Here we review present data for the efficacy and safety of this treatment modality.

Translated title of the contribution	Duodenal-jejunal bypass sleeve - a potential alternative to bariatric surgery?
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	176
Issue number	37
Pages (from-to)	1874-1877
Number of pages	4
ISSN	0041-5782
Publication status	Published - 29 Sept 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{049cd24c4bc946ca8d76d738ac7701b9,

title = "Behandling med duodenal-jejunal bypass-sleeve ved sv{\ae}r overv{\ae}gt",

abstract = "Overweight and obesity are risk factors for several co-morbidities reducing life expectancy. Conservative treatment of obesity is generally ineffective in the long-term. Bariatric surgery has proven effective, but is associated with potential complications. Duodenal-jejunal bypass sleeve is a novel minimal invasive and fully reversible endoscopic treatment modality approved for treatment of obesity with or without concomitant type 2 diabetes. Here we review present data for the efficacy and safety of this treatment modality.",

author = "Ulrich Rohde and Silas Gylvin and Peter Vilmann and Friis, {Steffen Ulrik} and Ebbe Langholz and Tina Vilsb{\o}ll and Knop, {Filip Krag}",

year = "2014",

month = sep,

day = "29",

language = "Dansk",

volume = "176",

pages = "1874--1877",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "37",

}

TY - JOUR

T1 - Behandling med duodenal-jejunal bypass-sleeve ved svær overvægt

AU - Rohde, Ulrich

AU - Gylvin, Silas

AU - Vilmann, Peter

AU - Friis, Steffen Ulrik

AU - Langholz, Ebbe

AU - Vilsbøll, Tina

AU - Knop, Filip Krag

PY - 2014/9/29

Y1 - 2014/9/29

N2 - Overweight and obesity are risk factors for several co-morbidities reducing life expectancy. Conservative treatment of obesity is generally ineffective in the long-term. Bariatric surgery has proven effective, but is associated with potential complications. Duodenal-jejunal bypass sleeve is a novel minimal invasive and fully reversible endoscopic treatment modality approved for treatment of obesity with or without concomitant type 2 diabetes. Here we review present data for the efficacy and safety of this treatment modality.

AB - Overweight and obesity are risk factors for several co-morbidities reducing life expectancy. Conservative treatment of obesity is generally ineffective in the long-term. Bariatric surgery has proven effective, but is associated with potential complications. Duodenal-jejunal bypass sleeve is a novel minimal invasive and fully reversible endoscopic treatment modality approved for treatment of obesity with or without concomitant type 2 diabetes. Here we review present data for the efficacy and safety of this treatment modality.

M3 - Tidsskriftartikel

C2 - 25294038

SN - 0041-5782

VL - 176

SP - 1874

EP - 1877

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 37

ER -

Behandling med duodenal-jejunal bypass-sleeve ved svær overvægt

Abstract

UN SDGs

Fingerprint

Cite this